MedWatch

Coloplast expects 28–30% operating margin in 2022/2023

The medtech company has revealed its full-year financials for 2021/2022, and has also presented a set of targets for next year, including a hoped-for organic revenue growth of 7–8%. (Updated)

Photo: Coloplast / PR

Coloplast has just concluded its financial year of 2021/2022, and has thus set ambitions for its next full-year accounting period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs